<DOC>
	<DOCNO>NCT00651456</DOCNO>
	<brief_summary>Our hypothesis addition bevacizumab standard chemotherapy treatment MPM improve overall survival quality life beyond achieved chemotherapy alone .</brief_summary>
	<brief_title>Mesothelioma Avastin Plus Pemetrexed-cisplatin Study</brief_title>
	<detailed_description>A phase II trial associate reference chemotherapy ( pemetrexed plus cisplatin ) bevacizumab need ensure specific toxicity induce association , triplet interesting activity . As pleural mesoth√©lioma rare tumor , phase III trial , use survival data phase II part study , able include sufficient number patient , reasonable period time , answer question efficacy anti-angiogenic triplet , provide efficacy outcome could consider favorable , end phase II part study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Malignant , histologically prove , non resectable pleural Mesothelioma In case pleural effusion , talc pleurodesis , although recommend , allow accordance current local practice , time diagnostic thorascopy , inclusion CT scan perform pleurodesis . ECOG Performance status 02 Mesothelioma pleural effusion without uni bidimensionally measurable disease eligible ( adapted RECIST criterion ) At least 18 year age , less 76 year age Radiation therapy thoracocentis tract ( 3 x 7Gy ) perform begin medical study treatment , interval thoracoscopic procedure radiation exceed 28 day Prior chemotherapy Brain metastasis History cerebral vascular accident ( CVA ) transient ischemic attack</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>